MA27706A1 - Procede de preparation de la duloxetine et intermediaires destines a etre utilises dans ledit procede - Google Patents

Procede de preparation de la duloxetine et intermediaires destines a etre utilises dans ledit procede

Info

Publication number
MA27706A1
MA27706A1 MA28400A MA28400A MA27706A1 MA 27706 A1 MA27706 A1 MA 27706A1 MA 28400 A MA28400 A MA 28400A MA 28400 A MA28400 A MA 28400A MA 27706 A1 MA27706 A1 MA 27706A1
Authority
MA
Morocco
Prior art keywords
duloxetine
acid addition
addition salt
intermediates
preparation
Prior art date
Application number
MA28400A
Other languages
English (en)
Inventor
Dharmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9949985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27706(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of MA27706A1 publication Critical patent/MA27706A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un procédé pour la préparation de (+)duloxetine, ou son sel enrichi en acide. Ledit procédé comprend la résolution de (??)duloxetine racémique avec un acide chiral de manière à obtenir un sel de l'acide chiral et le (+)duloxetine, considérablement libre de (-)duloxetine ; et (ii) si l'on veut, la conversion du sel préparé à l'étape (i) en base libre ou en un autre sel enrichi en acide selon ce qui est approprié. Le procédé de préparation de (+)duloxetine ou son sel enrichi en acide, peut en outre comprendre une étape d'un procédé intermédiaire d'O-alkylation réalisée en présence d'une base et d'un catalyseur de transfert de phase.
MA28400A 2002-12-19 2005-07-18 Procede de preparation de la duloxetine et intermediaires destines a etre utilises dans ledit procede MA27706A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0229583.0A GB0229583D0 (en) 2002-12-19 2002-12-19 A process for preparing duloxetine and intermediates for use therein

Publications (1)

Publication Number Publication Date
MA27706A1 true MA27706A1 (fr) 2006-01-02

Family

ID=9949985

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28400A MA27706A1 (fr) 2002-12-19 2005-07-18 Procede de preparation de la duloxetine et intermediaires destines a etre utilises dans ledit procede

Country Status (24)

Country Link
US (1) US7645890B2 (fr)
EP (2) EP1690861B1 (fr)
JP (1) JP5259048B2 (fr)
KR (1) KR100926723B1 (fr)
CN (2) CN100579975C (fr)
AT (1) ATE353081T1 (fr)
AU (2) AU2003292396B2 (fr)
BR (1) BR0316902A (fr)
CA (1) CA2510750A1 (fr)
DE (1) DE60311599T2 (fr)
ES (1) ES2279971T3 (fr)
GB (1) GB0229583D0 (fr)
HR (1) HRP20050657A2 (fr)
IL (1) IL169232A (fr)
IS (1) IS7915A (fr)
MA (1) MA27706A1 (fr)
MX (1) MXPA05006659A (fr)
NZ (2) NZ569874A (fr)
PL (1) PL377380A1 (fr)
PT (1) PT1587801E (fr)
RU (1) RU2351594C2 (fr)
TN (1) TNSN05167A1 (fr)
WO (1) WO2004056795A1 (fr)
ZA (1) ZA200505656B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550605B2 (en) * 2004-08-05 2009-06-23 Sun Pharmaceutical Industries Ltd. Process for preparation of an anitdepressant compound
CZ297560B6 (cs) * 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
WO2006071868A2 (fr) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Processus de preparation de sels de duloxetine repondant aux normes pharmaceutiques et d'intermediaires de ceux-ci
US20060270859A1 (en) * 2005-01-27 2006-11-30 Santiago Ini Duloxetine HCl polymorphs
WO2006096809A1 (fr) 2005-03-08 2006-09-14 Teva Pharmaceutical Industries Ltd. Formes cristallines de dnt-oxalaldehyde et procedes permettant de produire des formes cristallines de dnt-oxalaldehyde
EP1858859A1 (fr) 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Procede de preparation du compose optiquement actif (s)-(+)-n,n-dimethyl-3-(1-naphtalenyloxy)-3-(2-thienyl)propanamine
US8093408B2 (en) * 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US8153824B2 (en) * 2005-06-22 2012-04-10 The Wockhardt Company Antidepressant oral liquid compositions
US7842717B2 (en) 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
US7759500B2 (en) * 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
ATE507215T1 (de) * 2005-12-12 2011-05-15 Medichem Sa Verbesserte synthese und zubereitungen von duloxetinsalzen
CZ299270B6 (cs) 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
WO2007077580A2 (fr) * 2006-01-06 2007-07-12 Msn Laboratories Limited Procédé amélioré pour la préparation de chlorhydrate de duloxetine pur
US7538232B2 (en) 2006-01-19 2009-05-26 Eli Lilly And Company Process for the asymmetric synthesis of duloxetine
EP1976845A2 (fr) * 2006-02-13 2008-10-08 Teva Pharmaceutical Industries Ltd Processus pour la preparation de (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, un intermediaire de la duloxetine
HU228458B1 (en) * 2006-03-13 2013-03-28 Egis Gyogyszergyar Nyrt Duloxetine salts for producing pharmaceutical compositions
DE602006015617D1 (de) 2006-05-05 2010-09-02 Fidia Farmaceutici Verfahren zur Herstellung eines Zwischenprodukts für die asymmetrische Synthese von (+)Duloxetine
MX2008001079A (es) * 2006-05-23 2008-03-19 Teva Pharma Polimorfos de hidrocloruro de duloxetina.
WO2008004191A2 (fr) 2006-07-03 2008-01-10 Ranbaxy Laboratories Limited Procédé de préparation de duloxétine et de ses sels
CZ300116B6 (cs) * 2006-12-05 2009-02-11 Zentiva, A. S. Zpusob cištení hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
CN101657438A (zh) 2006-12-22 2010-02-24 斯索恩有限公司 制备度洛西汀和相关化合物的方法
HU227730B1 (en) 2006-12-22 2012-01-30 Richter Gedeon Nyrt Process for the preparation of duloxetine and for their the intermediates
WO2008107911A2 (fr) 2007-03-05 2008-09-12 Lupin Limited Nouveau procédé de préparation du chlorhydrate de duloxétine
WO2009019719A2 (fr) * 2007-08-09 2009-02-12 Ind-Swift Laboratories Limited Procédé de préparation de 3-aryloxy-3-arylpropanamines
WO2009130708A2 (fr) * 2008-04-22 2009-10-29 Shodhana Laboratories Limited Préparation de duloxétine et de ses sels
US8426178B2 (en) 2008-08-27 2013-04-23 Codexis, Inc. Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
US8288141B2 (en) 2008-08-27 2012-10-16 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
WO2011033366A2 (fr) 2009-09-16 2011-03-24 Jubilant Life Sciences Limited Procédé amelioré pour la préparation de duloxetine et de sel acceptable sur le plan pharmaceutique de celle-ci
CN103360365A (zh) * 2012-04-06 2013-10-23 李晓红 一种抗抑郁症药物原料药盐酸度洛西汀的制备新工艺
CN104230882B (zh) * 2014-08-29 2017-03-08 宁波美诺华药业股份有限公司 一种度洛西汀盐酸盐杂质的制备方法
CN104829587B (zh) * 2015-05-08 2017-07-21 上海万巷制药有限公司 盐酸度洛西汀的制备
CN107382958B (zh) * 2017-07-05 2021-11-09 浙江华海药业股份有限公司 一种度洛西汀中间体的结晶方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH578532A5 (fr) * 1971-08-03 1976-08-13 Cassella Farbwerke Mainkur Ag
FI77018C (fi) 1980-11-14 1989-01-10 Lilly Co Eli Analogifoerfarande foer framstaellning av antidepressivt aktiv (-)-enantiomer av n-metyl-n-/3-(2-metylfenoxi) -3-fenylpropyl/amin och dess farmaceutiskt godtagbara salt.
US4777291A (en) * 1985-02-27 1988-10-11 Eli Lilly And Company Racemization process
JPS62286959A (ja) * 1986-06-05 1987-12-12 Seitetsu Kagaku Co Ltd 光学活性シアノカルニチン塩の製造方法
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
IL98108A0 (en) * 1990-05-17 1992-06-21 Lilly Co Eli Chiral synthesis of 1-aryl-3-aminopropan-1-ols
JPH09176157A (ja) * 1992-12-09 1997-07-08 Takeda Chem Ind Ltd 光学活性アミノクマラン誘導体
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US6162949A (en) * 1994-12-16 2000-12-19 Uop Llc Process for preparation of the pharmaceutically desired (S)-oxetine enantiomers
US6458955B1 (en) * 1994-12-16 2002-10-01 Uop Llc Process for preparation of pharmaceutically desired enantiomers
EP0792649A1 (fr) * 1996-02-29 1997-09-03 Eli Lilly And Company Traitement de l'insomnie
UA78181C2 (en) * 1998-05-22 2007-03-15 Lilly Co Eli Combined therapy for treating refractory depressive states
DE69905938T2 (de) * 1998-11-13 2003-11-13 Eli Lilly And Co., Indianapolis Kombination von duloxetin mit nichtsteroid-entzündungshemmern für die behandlung von schmerz
JP2002541235A (ja) * 1999-04-09 2002-12-03 イーライ・リリー・アンド・カンパニー ３−アリールオキシ−３−アリールプロピルアミン及びその中間体の製造方法
US6677485B2 (en) * 1999-12-17 2004-01-13 Ranbaxy Laboratories Limited Process for the preparation of fluoxetine hydrochloride
WO2003062219A1 (fr) * 2002-01-24 2003-07-31 Eli Lilly And Company Procede de preparation d'un produit intermediaire utile pour la synthese asymetrique de duloxetine

Also Published As

Publication number Publication date
EP1690861A3 (fr) 2006-09-06
BR0316902A (pt) 2005-10-25
CN101125848A (zh) 2008-02-20
DE60311599T2 (de) 2007-10-25
EP1587801B1 (fr) 2007-01-31
RU2351594C2 (ru) 2009-04-10
IS7915A (is) 2005-06-24
JP2006514030A (ja) 2006-04-27
US20060205956A1 (en) 2006-09-14
AU2010200142A1 (en) 2010-02-04
NZ569874A (en) 2009-11-27
ES2279971T3 (es) 2007-09-01
EP1690861B1 (fr) 2012-09-12
MXPA05006659A (es) 2006-02-22
CN1747947A (zh) 2006-03-15
GB0229583D0 (en) 2003-01-22
KR100926723B1 (ko) 2009-11-16
JP5259048B2 (ja) 2013-08-07
ATE353081T1 (de) 2007-02-15
KR20050089839A (ko) 2005-09-08
HRP20050657A2 (en) 2005-10-31
ZA200505656B (en) 2006-04-26
DE60311599D1 (de) 2007-03-22
NZ540881A (en) 2008-09-26
AU2003292396B2 (en) 2010-05-20
CN100579975C (zh) 2010-01-13
TNSN05167A1 (en) 2007-05-14
WO2004056795A1 (fr) 2004-07-08
PT1587801E (pt) 2007-04-30
EP1690861A2 (fr) 2006-08-16
CA2510750A1 (fr) 2004-07-08
US7645890B2 (en) 2010-01-12
RU2005122662A (ru) 2006-01-20
EP1587801A1 (fr) 2005-10-26
AU2003292396A1 (en) 2004-07-14
IL169232A (en) 2010-02-17
WO2004056795A8 (fr) 2005-08-11
PL377380A1 (pl) 2006-02-06
CN101125848B (zh) 2012-09-12
AU2010200142B2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
MA27706A1 (fr) Procede de preparation de la duloxetine et intermediaires destines a etre utilises dans ledit procede
EP2428519A3 (fr) Procédé de préparation de 17-vinyle-triflates en tant qu'intermédiaires
IS5883A (is) Aðferð til framleiðslu á hreinu sítalóprami
PT1038875E (pt) Derivados de imidazopiridina e processo para os preparar
TNSN08030A1 (fr) Procede de preparation de la 4b-amino-4'-demethyl-4- desoxypodophyllotoxine
ES2106835T3 (es) Procedimiento de preparacion de alfa-ceto-amidas.
IS6435A (is) Aðferð til framleiðslu á sítalóprami
ATE266020T1 (de) Synthese von r-(+)-alpha-liponsäure
BR0308345A (pt) Processo para derivados de ácido trans-4-amino-1-cicloexanocarboxìlico
EA200400739A1 (ru) Способ получения производных [1,4,5]оксадиазепина
FR2846325B1 (fr) Nouveau procede de preparation d'un intermediaire de synthese de pesticide
EP1211239A4 (fr) Procedes de preparation de composes 2,3-dihydroazepine
CN102276537B (zh) 2-氰基-5-氨基嘧啶的制备方法
BR0317781A (pt) Processo para produção de derivado de benzilamina
RU2007146394A (ru) Способы получения гетероциклических соединений
ATE249434T1 (de) Ein verfahren zur herstellung von pyrrolidinon- derivaten
SE8503811D0 (sv) Novel process for the preparation of an aminolactone
DE60124831D1 (de) Ein verfahren zur herstellung substituierter alkylamin-derivate
EP0378707A1 (fr) Derives d'aminoacetonitrile.
KR100592797B1 (ko) 3-메틸-4-페녹시페닐아민 유도체의 제조 방법
CN1207390A (zh) 含有β位三氟甲基基团的五元芳香杂环化合物及其合成
JPH10175913A (ja) 光学活性２−フェノキシプロピオン酸の製造方法
JPH02233692A (ja) 新規なｎ↑６，２′―ｏ―ジ置換―アデノシン―３′，５′―環状リン酸及びその製法
TH39355A (th) กรรมวิธีสำหรับการผลิต 3-n, n-ไดไซโคลบิวทิลอะมิโน-8-ฟลูออโร-3,4-ไดไฮโดร-2h-1-เบนโซไพเรน-5-คาร์บอกซาไมด์
EP0658542A4 (fr) PROCEDE DE PRODUCTION DE -g(a)-HYDROXYIMINOPHENYLACETONITRILE.